



On-demand learning

6 how-to videos to upgrade
your surgical skills **64**

**When itchy pets
present ...**

Get a complete history
with this comprehensive
clinic form **66**

Albuterol toxicosis

Calming a pit bull's
racing heart after exposure
to this bronchodilator **69**

Canine IQ

Are owners overestimating
their dogs' intellect? **74**

Idea Exchange

- ▶ A tie down trick for feline
abdominal surgery **86**
- ▶ Pain-free in-clinic blood
glucose curves **86**

Constipated **CATS**

**All the tools you need
to unclog kitties**

p75



UBM



GI DISEASE

Relief he's been waiting for



CLINICALLY PROVEN NUTRITION TO SOOTHE THE GI TRACT, WITH ADDED GINGER



HIGHLY DIGESTIBLE AND LOW IN FAT



PREBIOTIC FIBER PROMOTES GROWTH OF BENEFICIAL BACTERIA

PRESCRIPTION DIET®

i/d® Low Fat Canine

Nothing works harder on tough GI cases than the clinically proven power of **i/d Low Fat**:

- **Proprietary blend** that contains ginger
- **Omega-3 fatty acids** help break the cycle of inflammation

For more information, talk to your Hill's Representative.

©2015 Hill's Pet Nutrition, Inc. ®/™ Trademarks owned by Hill's Pet Nutrition, Inc.



HillsVet.com

Veterinary medicine®

Essential medicine for exemplary patient care

Mission

Veterinary Medicine is a peer-reviewed journal dedicated to providing concise, credible, and essential information on the most common and crucial clinical problems seen in companion-animal practice.

Editorial Advisory Board

Leading specialists who direct our content and ensure our editorial quality and integrity

Joseph W. Bartges, DVM, PhD, DACVIM, DACVN

David S. Bruyette, DVM, DACVIM

Barret Bulmer, DVM, MS, DACVIM

John Ciribassi, DVM, DACVB

Timothy M. Fan, DVM, DACVIM

Juliet R. Gionfriddo, DVM, MS, DACVO

Karen A. Moriello, DVM, DACVD

Jennifer Wardlaw, DVM, DACVS

Practitioner Advisory Board

Progressive practitioners who keep our content practical, timely, and relevant

Mili Bass, DVM, DABVP

Robin Downing, DVM

Corey Entriiken, DVM

Wayne L. Hunthausen, DVM

Thomas McCoy, DVM

Melissa M. Mckendry, DVM, DABVP

Fred L. Metzger Jr., DVM, DABVP

Robert M. Miller, DVM

Gary D. Norsworthy, DVM, DABVP

R. Wayne Randolph, VMD

Michael H. Riegger, DVM, DABVP

David Robbins, DVM

Philip VanVranken, DVM

Laura L. Wade, DVM, DABVP



Content Group

Editor/Medicine Channel Director | Mindy Valcarcel
mvalcarcel@advanstar.com

Medical Editor | Heather Lewellen, DVM

Content Manager | Adrienne Wagner

Senior Content Specialist | Alison Fulton

Assistant Content Specialists | Katie James | Matthew Kenwright

Technical Editor | Jennifer Vossman, RVT

Consulting Technical Editor | Avi Blake, DVM

Digital Channel Director | Jessica Zemler

Senior Designer/Web Developer | Ryan Kramer

Art Director | Shawn Stigsell

Multimedia Contributor | Troy Van Horn

Advanstar Veterinary

Vice President/General Manager | Becky Turner Chapman

Group Content Director | Mamette Falley

Medical Director | Theresa Entriiken, DVM

Director, Electronic Communications | Mark Eisler

Director, Marketing | Brenda Andresen

Director, The CVC Group | Peggy Shandy Lane

Sales Group

Sales Director | David Doherty

Senior Account Managers, Advertising

Terry Reilly | Chris Larsen

Account Manager, Advertising | Angela Paulovcin

Senior Account Manager, Projects | Jed Bean

Sales and Projects Coordinator | Anne Belcher

Books/Resource Guides | Maureen Cannon
(440) 891-2742

List Rental Sales | Renée Schuster
(440) 891-2613, rschuster@advanstar.com



UBM

Chief Executive Officer | Joe Loggia

Executive Vice President, Chief Administrative Officer

& Chief Financial Officer | Tom Ehardt

Executive Vice President | Georgiann DeCenzo

Executive Vice President | Chris DeMoulin

Executive Vice President, Business Systems | Rebecca Evangelou

Executive Vice President, Human Resources | Julie Molleston

Executive Vice-President, Strategy & Business Development | Mike Alic

Senior Vice President | Tracy Harris

Vice-President, General Manager Pharm/Science Group | Dave Esola

Vice President, Legal | Michael Bernstein

Vice President, Media Operations | Francis Heid

Vice-President, Treasurer & Controller | Adele Hartwick

Subscriber Services: Call (800) 815-3400 in the United States, or (888) 527-7008 or (218) 740-6477 in Canada; fax (218) 740-6417; or write to: *Veterinary Medicine*, 131 W. 1st St., Duluth, MN 55802-2065. If you are unable to connect with the 800 numbers, email fulfill@superfill.com. **Reprint Services:** Call 1-877-652-5295 ext. 121 or email bkolb@wrightsmedia.com. Outside US, UK, direct dial: 281-419-5725 ext. 121 **Back Issues:** Individual copies are available for one year; to order, call (800) 598-6008. Permissions/International Licensing. Call Maureen Cannon at (440) 891-2742. **List Sales:** Please contact List Account Executive Renée Schuster at (440) 891-2613. **Editorial Offices:** Write to 8033 Flint, Lenexa, KS 66214; or call (913) 871-3800. **Visit our websites:** dvm360.com; theccvc.com; industrymatter.com.


Veterinary Medicine (ISSN 8750-7943 print; ISSN 1939-1919 online) is published monthly by UBM Advanstar, 131 West First St., Duluth, MN 55802-2065. One year subscription rates: \$60 in the United States and Possessions; \$72 in Canada and Mexico; \$97 in all other countries. Single issue orders: \$18 in the United States and Possessions; \$22 in Canada and Mexico; \$24 in all other countries. Periodicals postage paid at Duluth, MN 55806 and additional mailing offices. POSTMASTER: Please send address changes to Veterinary Medicine, P.O. Box 6087, Duluth, MN 55806-6087. Canadian GST Number: R-124213133RT001. Publications Mail Agreement Number: 40612608. Return undeliverable Canadian addresses to: IMEX Global Solutions, P.O. Box 25542, London, ON N6C 6B2, Canada. Printed in the U.S.A. © 2015 UBM Advanstar. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical including by photocopy, recording, or information storage and retrieval without permission in writing from the publisher. Authorization to photocopy items for internal/educational or personal use, or the internal/educational or personal use of specific clients is granted by UBM Advanstar for libraries and other users registered with the Copyright Clearance Center, 222 Rosewood Dr. Danvers, MA 01923, 978-750-8400 fax 978-646-8700 or visit <http://www.copyright.com> online. For uses beyond those listed above, please direct your written request to Permission Dept. fax 440-756-5255 or email: mcannon@advanstar.com. UBM Advanstar provides certain customer contact data (such as customers' names, addresses, phone numbers, and e-mail addresses) to third parties who wish to promote relevant products, services, and other opportunities which may be of interest to you. If you do not want UBM Advanstar to make your contact information available to third parties for marketing purposes, simply call toll-free (866) 529-2922 between the hours of 7:30 a.m. and 5 p.m. CST and a customer service representative will assist you in removing your name from UBM Advanstar's lists. Outside the United States, please call (218) 740-6477. Veterinary Medicine does not verify any claims or other information appearing in any of the advertisements contained in the publication, and cannot take responsibility for any losses or other damages incurred by readers in reliance on such content. Publisher assumes no responsibility for unsolicited manuscripts, photographs, art, and other material. Unsolicited material will not be returned. Address correspondence to Veterinary Medicine, 8033 Flint, Lenexa, KS 66214; (913) 871-3800; e-mail vm@advanstar.com. To subscribe, call toll-free 888-527-7008. Outside the U.S. call 218-740-6477.

6 how-to surgery videos *at your fingertips*

In a partnership with the Oquendo Center in Las Vegas, Nevada, *Veterinary Medicine* worked with Don Waldron, DVM, DACVS, chief medical officer of the Western Veterinary Conference, to capture six step-by-step videos on common surgeries. Find them all at dvm360.com/waldron-video.




Tracheotomy with tracheostomy tube placement in dogs




Canine gastrotomy




Canine mandibular and sublingual salivary gland excision



Canine gastrotomy tube placement



Incisional gastropexy



Canine scrotal urethrostomy



HARVEST® PRP CELLULAR THERAPY

Introducing Harvest SmartPrep System: The Gold Standard

Harvest Technologies is the leader in developing point-of-care cellular platforms to isolate and concentrate autologous growth factors, stem cells, and accessory cells that may help optimize conditions for healing.

A decade ago, we introduced the Harvest SmartPrep System, making the use of autologous growth factors practical for the first time. Today, the Harvest SmartPrep System platform is the gold standard in PRP technology and is now available for canines.

A System To Process Optimal Platelet Concentrate For Natural Healing

Harvest Ordering Information

SMP2-115-01	Harvest SmartPrep System 110V - 50/60 Hz
V-APC-30-01	Harvest PRP Procedure Pack for SmartPrep System Generates 3-4ml PRP. 1/case



Contact your Terumo Representative at **1.800.888.3786** or visit us at **www.terumotmp.com** and click on Find Your Local Terumo Rep.



Harvest SmartPrep System Video
Scan to see this technology in action

TERUMO and TERUMO are trademarks owned by Terumo Corporation, Tokyo, Japan, and they are registered with the U.S. Patent & Trademark Office. HARVEST is a trademark owned by Harvest Technologies Corporation, Plymouth, MA. SMARTPREP is a trademark owned by Harvest Technologies Corporation, Plymouth, MA and is registered with the U.S. Patent & Trademark Office. ©2015 Terumo Medical Corporation 2/15. All rights reserved. Approval # TMP-0043-02062015

HARVEST
TERUMO
Advancing Cellular Therapies™

TERUMO®

TERUMO MEDICAL PRODUCTS

The importance of taking a complete dermatologic history

And how to do it right—including a comprehensive downloadable client history form. *By Douglas J. DeBoer, DVM, DACVD*



Hear all about it!

Listen to Dr. DeBoer discuss what cues in the patient history should make you suspect atopic dermatitis by scanning the QR code below or by visiting dvm360.com/CVCADHistory.



Taking a thorough patient history is fundamental in assessing patients with skin disease. The clinical signs, age of onset, duration, location and extent of pruritus, treatments already used, and many more factors are often valuable clues for diagnosis. Obtaining all of the necessary information

is a time-consuming task that may seem impossible to accomplish in a brief office visit.

Using a dermatology history form is greatly helpful in this regard (visit dvm360.com/DermHistoryForm to download a form you can use in your clinic). The form is intended to be filled out in

advance by the client—in the waiting room or perhaps even at home if it is available as a download from the clinic website. It's easy and quick to review the form before entering the examination room. Then, taking the history is a matter of clarifying points of uncertainty, expanding on others, and summarizing your

understanding to the owner. The following are some major points to consider.

Major client complaint

Is it itching? Hair loss? Lesions? All of the above? Regardless of your overall findings, make sure to address the client's major concern.

Description of disease onset

When, where, and how did it start? Did the itch come first and then the lesions? Or was it the reverse? Or both at the same time?

- Parasites or infections can occur at any age. A young onset may favor allergy. An older onset may signify underlying systemic, metabolic, or autoimmune disease. Geriatric patients may lead you to consider skin neoplasia or a paraneoplastic syndrome.
- Itch first without lesions tends to favor allergic causes. Lesion appearance first or at the same time as itch tends to favor parasitic or infectious causes.


(Patient label information here)

DERMATOLOGY HISTORY FORM
Date _____
Your name _____

- What skin or ear problem are you bringing your pet in for? _____
- How long has the problem been present? _____ How old was your pet when the problem first started? _____
- When the problem started, did it come on suddenly or gradually over a period of time? _____
- What did the skin or ear problem look like initially? _____
- How has it changed or spread? _____
- The problem has been checked on: _____
☐ Constant, even with medication ☐ Constant but better with medication ☐ Intermittent or sporadic
- Is the problem worse during certain times of the year? If so, when? _____
- Over the past year, how itchy has your pet been during a typical outbreak of skin or ear disease? Use a scale of 1 to 10 with 1 meaning an occasional scratch, like a normal person or animal might do, and 10 meaning constant, severe scratching. _____
- Using the same 1 to 10 scale, how itchy has your pet been over the past month? _____
- Is your pet receiving any treatment now? If yes, what kind? _____
- When did your pet last receive any medication, and what medication was it? _____
- What do you feed your pet now? _____
- Have any different diets been tried as treatment? If so, list the brand name and for how long you fed it: _____
- How often do you usually bathe your pet? With what? _____
- When was the last time you saw a flea on your pet or another pet in the household? _____
- Do you routinely use flea or tick preventive products on your pet (list type)? _____
- How old was your pet when you obtained him/her? Where did you get your pet? _____
- What other pets are in the household? _____
- Do any of the other pets have skin problems? Do any people in the household have skin problems? _____
- What percentage of the day and night does your pet spend indoors vs. outdoors? Indoors ____% Outdoors ____%
- Other than skin disease, does your pet have any diagnosed medical problems? _____
- Please list any other clinical signs your pet has that have not been described above or anything else you suspect might be contributing to your pet's skin or ear disease? _____

PLEASE TURN OVER AND CONTINUE ON REVERSE SIDE.

Go to dvm360.com/DermHistoryForm to download and use this dermatology history form to make sure you're capturing all the information you need at each itchy pet visit.



OBESITY



FLUTD

Let's treat
them **together**



REDUCES BODY WEIGHT
BY 11% IN 60 DAYS¹



REDUCES THE RECURRENCE
OF FIC SIGNS BY 89%²

NEW PRESCRIPTION DIET®
Metabolic+Urinary

Meet the world's only proven single solution for both.
Together we can help all of your patients at risk.

For more information, talk to your Hill's Representative.



¹Data on file, Hill's Pet Nutrition, Inc.
²Kruger JM, Lulich JP, Merrills J, et al. *Proceedings American College of Veterinary Internal Medicine Forum* 2013.
©2014 Hill's Pet Nutrition, Inc. ®/™ Trademarks owned by Hill's Pet Nutrition, Inc.



Tastes like



Works like



**Metabolic
+Urinary**

**There's never been
therapeutic nutrition
like this.**

- ✓ Irresistible new form
- ✓ Full strength, clinically proven efficacy



HillsVet.com

©2015 Hill's Pet Nutrition, Inc.

®/™ Trademarks owned by Hill's Pet Nutrition, Inc.

COMING SOON

CVC HIGHLIGHT

- Parasites or infections are typically a sudden onset, while allergic causes are usually gradual onset.

Description of skin disease progression

Be sure to note any changes with season or with medication. Seasonality may suggest environmental allergy, and a response (or lack of response) to prior treatments may provide clues.

Degree and location of pruritus

The distribution may be highly suggestive. For example, a dorsal lumbosacral focus can often be assumed to be flea allergy until proven otherwise, while pedal or pinnal pruritus is suggestive of environmental or food allergy. For dogs, some history forms may incorporate the Favrot criteria for clinical evidence of atopic dermatitis.¹

Current and prior treatments and response

Be sure to ask about different diets that have been tried. Was a complete and proper hypoallergenic diet trial performed (*i.e.* with strict compliance and a veterinary therapeutic diet)?

Parasite history and current parasite control—or lack thereof

For pruritic skin disease in dogs and cats, instituting regular parasite control is a standard recommendation.

Evidence of contagion to other animals or people

Any evidence of contagion signals a parasite or dermatophyte infection.

Clinical signs the owner has observed

Be sure to assess the severity of the signs as well. Using a grid- or table-like form enables you to quickly scan down to see the signs that are “moderate” or “severe.”

Evidence of concurrent disease

Is there any suggestion of underlying disease? Gastrointestinal signs that may encourage consideration of food allergy as a cause?

Owner's thoughts on the cause of the disease

At the very least, you may be able to assure the owner of what is not causing the pet's illness, such as allergy to carpet fibers, perfumed laundry detergent, fabric softener sheets, or other urban myths.

Closing thoughts

The other big advantage of a history form is that you now have all the information for every patient all in the same location in the record. Months later, if you need to look back to see how the client rated the dog's pruritus or whether other diets were tried, you'll know exactly where to find the information. **VM**

Reference

1. Favrot C, Steffan J, Seewald W, et al. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. *Vet Dermatol* 2010;21(1):23-31.

*Douglas J. DeBoer, DVM, DACVD
Department of Medical Sciences
School of Veterinary Medicine
University of Wisconsin
Madison, WI 53706*

Albuterol toxicosis in a pit bull terrier

By Brandy R. Sobczak, DVM

A 2-year-old 58.7-lb (26.5-kg) spayed female pit bull terrier was presented to an emergency clinic for evaluation of panting and what the owner suspected to be tachycardia, since the owner felt like the dog's heart was racing.

HISTORY

About five hours earlier, the owner had discovered an aerosol albuterol inhaler (90 µg/actuation) in the dog's crate with two punctures in it. The owner had used this inhaler only a couple of times. The dose of albuterol the dog was exposed to could not be determined.

The dog had a history of allergies and atopy. It was receiving prednisone every other day.

PHYSICAL EXAMINATION AND DIAGNOSTIC TESTS

At presentation, the dog was tachycardic with a heart rate of 220 bpm and was panting. Its body temperature was normal (100.4 F). The conjunctiva was hyperemic bilaterally, and its digits were erythematous. The patient had areas of multifo-

cal alopecia (suspected to be secondary to allergies). Abnormal laboratory results included hypokalemia (serum potassium = 2.6 mmol/L; normal range = 3.4 to 4.9 mmol/L), hyperglycemia (serum glucose = 121 mg/dl; normal range = 60 to 115 mg/dl), metabolic acidosis (blood pH, venous = 7.304; normal range = 7.35 to 7.45), and base excess (-8; normal range = -5 to 0).

TREATMENT

The dog was admitted to the hospital for treatment of tachycardia, electrolyte concentration monitoring, and supportive care. Plasma-Lyte (Baxter) intravenous fluids, supplemented with 40 mEq/L of potassium chloride, were administered at 90 ml/hr, and 10 mg of propranolol (0.37 mg/kg) was given orally since the intravenous form was not available. The patient's heart rate, blood pressure, and electrolyte concentrations, including serum potassium and phosphorus, were monitored over the next 18 hours.

Within two hours of giving the propranolol, the dog's heart rate was approximately 160 bpm

and then remained 150 bpm or less for the duration of hospitalization. The panting resolved within two hours of initiating treatment, and the conjunctival hyperemia resolved as well.

Within five hours of presentation, the acidosis had resolved, but the patient's potassium concentration was still slightly low (3.3 mmol/L). Within nine hours of presentation, the serum potassium concentration was normal (4.2 mmol/L). The potassium chloride supplementation within the Plasma-Lyte was then changed to 20 mEq/L. The dog's blood pressure and electrocardiogram (ECG) remained normal throughout hospitalization.

The patient was discharged 18 hours after being admitted to the hospital.

DISCUSSION

Albuterol toxicosis is common in dogs because dogs



tend to chew on albuterol-containing inhalers and the liquid vials used in nebulizers. Since 2002, the ASPCA Animal Poison Control Center (APCC) has received more than 4,000 calls about albuterol exposures. More than 95% of these calls involved dogs (ASPCA APCC Database: Unpublished data, 2002-2013).

Pathophysiology

Albuterol is a beta-adrenergic agonist used primarily in veterinary medicine as a bronchodilator in dogs, cats, and horses.¹ Recommended doses in dogs range from 0.02 to 0.05 mg/kg orally every eight to 12 hours.

In overdose situations, the selectivity for beta-2 receptors is lost, and albuterol will stimulate both beta-1 and beta-2 receptors.

For inhalation in a 60-lb dog, 0.5 ml of a 0.5% solution for nebulization mixed in 4 ml of saline can be nebulized every six hours.¹

Beta-adrenergic receptors are divided into mainly two types: beta-1 and beta-2. Beta-1 receptors are found within the myocardium and control the heart rate and contractility. Beta-2 receptors are located primarily within the smooth muscles of the blood vessels,

airways, gastrointestinal tract, and genitourinary system. There are also beta-2 receptors within the heart, liver, and skeletal muscles.² These receptors are responsible for the relaxation of the uterine and bronchial smooth muscles and for vasodilation.³

Albuterol is a selective beta-2 receptor agonist. When used to treat bronchoconstriction, beta-adrenergic agonists bind to the beta-2 receptors located on the bronchial smooth muscle. This binding stimulates a conversion of adenosine triphosphate into cyclic adenosine monophosphate. Increased cyclic adenosine monophos-

phate causes bronchial muscle cells to relax, resulting in bronchodilation.^{4,5}

Even with therapeutic doses, clinical effects may include transient hypotension, reflex tachycardia, and mild muscle tremors, in addition to the desired bronchodilation, because of multiple beta-2 receptor binding sites within the body.⁵ In overdose situations, the selectivity for beta-2 receptors is lost, and albuterol

will stimulate both beta-1 and beta-2 receptors.


Clinical signs

Clinical signs associated with overstimulation of both beta-1 and beta-2 receptors, as well as catecholamine release, can include tachycardia, hypotension, hypertension, muscle tremors, vomiting, tachypnea, agitation, hyperactivity, arrhythmias (most commonly supraventricular tachycardia), lethargy, and weakness. This muscle weakness and lethargy could be secondary to hypokalemia or discomfort from the tachycardia and a result of poor cardiac output secondary to significant tachycardia, myocardial fatigue, or myocardial ischemia. Patients that do not receive prompt treatment for supraventricular tachycardia may be more likely to develop ventricular arrhythmias.

Hypokalemia may develop secondary to an intracellular shift of potassium and could contribute to arrhythmias seen in some patients. Hypophosphatemia may also be seen, and it is also thought to be from intracellular movement.^{2,5}

Treatment and monitoring

Since the ventricular tachycardia in albuterol toxicosis occurs from the overstimulation of beta receptors, both beta-1 and beta-2 receptors are involved.

A black and white dog, possibly a Springer Spaniel, is sitting on a green lawn next to a person's legs wearing blue jeans and brown shoes. The dog is looking up at the person. A blue leash is attached to its collar. The background shows a tree trunk and a paved path.

"That's just my [SUPRESSED IMMUNE SYSTEM.
ELEVATED HEART RATE. ABNORMAL RESPIRATORY
RATE. GI UPSET. HORMONE CHANGES.
INAPPETANCE.] stress coming out."

Start a new dialogue about behavior then start new Zylkene®.

Because your patients aren't just stressed out. They're stressed within. Your clients don't realize behavior problems aren't just stress-related, they're health-related too. You're the life line for answers and new Zylkene is your first line:



- The only veterinary nutraceutical with alpha-casozepine, a safe and natural ingredient derived from casein, a milk protein with calming properties
- Clinically proven for behavioral problem management without drowsiness or sedation
- Indicated for situational stress or chronic anxiety in dogs or cats
- Palatable, once-daily formulation in three sizes

Learn more at vetoquinolusa.com/zylkene or call 800-267-5707.

Relax, you've got **Zylkene®**

Vétoquinol
a Sign of Passion

Propranolol works well to treat these signs. Propranolol is a nonspecific beta-blocking agent, which means it can block both beta-1 and beta-2 receptors. Therapeutic doses range from 0.02 mg/kg slowly intravenously up to a maximum of 0.1 mg/kg in dogs and cats, 0.1 to 0.2 mg/kg orally in dogs up to a maximum of 1.5 mg/kg every eight hours, and 2.5 to 10 mg total in cats every eight to 12 hours.¹

An alternative medication used to treat the clinical signs of albuterol toxicosis is esmolol. Esmolol is a specific beta-1 adrenergic blocker that is used to control ventricular arrhythmias. It can be administered to dogs as an initial slow intravenous bolus of 0.25 to 0.5 mg/kg over one or two minutes, followed by a constant rate infusion of 0.01 to 0.2 mg/kg/min.¹

Monitoring serum electrolyte concentrations, especially potassium and phosphorus, is important because many patients exposed to albuterol develop hypokalemia and hypophosphatemia. Hypokalemia and hypophosphatemia likely occur secondary to intracellular shifts, so use caution to not oversupplement intravenous fluids with potassium chloride or phosphorous. If the potassium concentration is < 2.5 mEq/L, then supplementation with potassium chloride is needed. The phosphorus concentra-

tion will often correct when the potassium concentration is corrected. Monitor electrolyte concentrations every four to six hours until they are normal.

Stimulatory signs such as tremors, hyperactivity, and agitation are often well-controlled with benzodiazepines such as diazepam (0.5 to 1 mg/kg intravenously) or midazolam (0.1 to 0.5 mg/kg intravenously).¹ Signs of muscle weakness and lethargy often resolve once the patient's electrolyte concentrations and heart rate are regulated.

Administering activated charcoal is usually not practical after exposure to an albuterol inhaler or albuterol liquids because albuterol is absorbed rapidly and does not undergo enterohepatic recirculation. If an animal ingests albuterol-containing tablets and is asymptomatic, then induce emesis by administering 3% hydrogen peroxide (2.2 ml/kg orally, repeat once if emesis does not occur the first time) or apomorphine (into the conjunctival sac or intravenously [0.03 to 0.04 mg/kg]).¹ Then follow that with the administration of activated charcoal (2 to 3 g/kg orally).

Monitoring these patients' ECGs is also recommended, as some animals can develop ventricular premature contractions. If ventricular premature contractions are seen, lidocaine can be given

intravenously at 2 to 8 mg/kg slowly followed by a constant rate infusion of 25 to 75 µg/kg/min in dogs. Use caution when giving this medication to cats since it can result in seizures and cardiovascular changes. Therapeutic doses in this species are 0.25 to 0.5 mg/kg slowly intravenously.¹


Prognosis

The prognosis for dogs with albuterol toxicosis that receive prompt treatment is generally good. Clinical signs may persist for 24 to 48 hours, depending on the albuterol dose consumed. If the patient develops arrhythmias or has underlying cardiac disease, clinical signs may persist longer, and the prognosis may be guarded. **VM**

REFERENCES

1. Plumb DC. *Plumb's veterinary drug handbook*. 7th ed. Stockholm, Wisconsin: PharmaVet Inc, 2011.
2. Mensching D, Volmer PA. Breathe with ease when managing beta-2 agonist inhaler toxicoses in dogs. *Vet Med* 2007;102(6):369-373.
3. Brunton LL, Lazo JS, Parker KL. *Goodman & Gilman's the pharmacological basis of therapeutics*. 11th ed. New York: McGraw-Hill, 2006;164-167.
4. Olson J. *Clinical pharmacology made ridiculously simple*. 2nd ed. Miami, Florida: MedMaster Inc, 2003;86.
5. Rosendale M. Bronchodilators. In: Plumlee KH, ed. *Clinical veterinary toxicology*. St. Louis: Mosby, 2004;305-307.

Brandy R. Sobczak, DVM
ASPCA Animal Poison
Control Center
1717 S. Philo Road, Suite 36
Urbana, IL 61802



for getting a loan from someone who understands your practice.

Business Borrowing | for the achiever in you®

Get financing from a banker who understands your practice and the importance of cash flow to help it succeed. PNC provides dedicated and experienced Healthcare Business Bankers who understand the financial needs of a successful practice, so you end up with more than just a loan, you end up with customized financing solutions.

For more information about how you can optimize your practice's cash flow, contact a Healthcare Business Banker at 877-566-1355 or go to pnc.com/hcprofessionals

PNC|CFOSM
Cash Flow Optimized



All loans and lines of credit subject to credit approval and require automatic payment deduction from a PNC Bank business checking account. Origination and annual fees may apply. Cash Flow Optimized is a service mark of The PNC Financial Services Group, Inc. ©2015 The PNC Financial Services Group, Inc. All rights reserved. Bank deposit products and services provided by PNC Bank, National Association. Member FDIC

Canine intelligence from the pet owner's perspective—and *why we need to care*

Why they did it

Owners may better interpret canine behavior if they have an improved understanding of dogs' cognitive abilities. A group of researchers decided to investigate dog owners' perceptions of their dogs' intelligence.

What they did

Using an online survey, researchers collected data from 645 participants worldwide. Most respondents were women (90.1%) with a mean age of 41.9 years, and most were university-educated. Most respondents were born in Australia (61.5%); the United States (18.5%) and the United Kingdom (9.9%) were the next most frequently represented. Only data from owners currently living with a dog were included in the study, and most had lived with their dogs for at least three years.


In addition to demographic questions including level of education and location of primary dwelling, the survey included questions intended to “determine respondent beliefs with regard to whether dogs had an instinctive or learned ability to perform certain actions across several cognitive domains, including communication with humans, understanding of human attentional focus, problem solving learning

and memory, social learning, means-end awareness, tool use, deception, mirror self-recognition, and empathy/emotional recognition.” The final section of the survey was designed to assess the dog-owner relationship and perceived emotional closeness.

What they found

Overall, respondents agreed that dogs possess extensive social cognitive skills despite the fact that some of these, such as the belief that dogs are capable of recognizing human emotion, have not been demonstrated in scientific research. About one-quarter of respondents agreed or strongly agreed that dogs are smarter than most people. Owners who were emotionally close to their dogs and had a higher self-reported knowledge of dogs perceived dogs as having greater cognitive skills compared with people who were less close to their dogs. However, owners with higher self-reported knowledge of dogs thought dogs were *less* capable of instinctive problem-solving.

The researchers acknowledge some of the limitations of the study, such as not separating instinctive versus learned skills, which may have affected the



scoring. The demographic data of the respondents may have also introduced bias and may make the data less applicable to the general public worldwide. In addition, since participants were recruited through social media and dog-related online forums, the data may be biased toward people who are very interested in canine cognition and behavior.

Take-home message

Inappropriate behavior is a common cause of relinquishment to animal shelters. A broader knowledge base of what is normal dog behavior as well as a greater understanding of owners' perceptions of that behavior will allow veterinarians and pet care givers to better educate the public about dog ownership.

Howell TJ, Toukhsati S, Conduit R, et al. The perceptions of dog intelligence and cognitive skills (PoDlaCS) survey. *J Vet Behav* 2013;8(6):418-424.



This “Journal Scan” summary was contributed by Jennifer L. Garcia, DVM, DACVIM, a veterinary internal medicine specialist at Sugar Land Veterinary Specialists & Emergency Care in Houston, Texas.

ALL BUNGED UP: Unclogging the constipated cat

Uncomfortable for all involved, constipation in cats is solvable once you determine the cause—be it medical or behavioral. All the tools you need to unclog kitties are right here. *By Margie Scherk, DVM, DABVP (feline practice)*

Straining in the litter box—possibly even crying out or leaving unwelcome hard pellets around the home—constipated felines are uncomfortable. And constipation can interfere with a cat's appetite and even result in vomiting. Traditional approaches to this hard problem include administering enemas, laxatives to soften the stool or increase contractions, dietary fiber, and promotility agents. Could we be missing something really basic? And when should we be concerned about long-term effects of constipation?

CAUSES OF CONSTIPATION

Constipation is a clinical sign that is not pathognomonic for any particular cause. Most commonly, constipation is a



result and sign of dehydration. The body is 65% to 75% water, depending on a cat's age and percent body fat. Homeostasis attempts to maintain a consistent cellular and extracellular environment. When cells become dehydrated, the body takes steps to correct the fluid deficit. Drinking more and concentrating urine are helpful, but once those capabilities have

been maximized, water is reabsorbed in the colon, resulting in drier stool that is harder to pass. Bearing this in mind, medical therapy might not be the best initial therapeutic approach.

Other causes of constipation include problems that result in obstruction (either mechanical or functional), painful defecation, stress within the home environment (social or a dirty

Find it all here
dvm360
Client video

Dr. Scherk enlists your cat clients in watching out for their pets' health by discussing the signs of constipation they can look for at home. Scan the QR code below, or go to dvm360.com/CloggedCatVideo.



Table 1
Processes resulting in constipation

Mechanism	Examples
Increased water loss	<ul style="list-style-type: none"> • Diuretic drugs • Polyuria from chronic kidney disease, diabetes mellitus, hyperthyroidism • Vomiting
Inadequate water intake	<ul style="list-style-type: none"> • Inadequate amount or quality of water available or lack of access to water (social stress or limited mobility) • Diet excessively dry or high in insoluble fiber • Painful drinking from orodental disease or difficulties swallowing
Painful defecation	<ul style="list-style-type: none"> • Degenerative joint disease; diseases of anal glands, prostate, rectum
Reluctance to defecate	<ul style="list-style-type: none"> • Social competition or fear of being ambushed • Unpleasant litter box (e.g. dirty, negative association with painful urination or defecation, inadequate size, covered box, dislike of litter type, suboptimal location) • Hospitalization
Obstruction—mechanical	<ul style="list-style-type: none"> • Intraluminal foreign body, neoplasia, stricture, polyp • Mural thickening (neoplasia, inflammation), intussusception, diverticulum, or hernia • Extra-intestinal compression by neoplastic or other mass, pelvic fracture, prostatic disease
Obstruction—functional	<ul style="list-style-type: none"> • Drugs resulting in decreased motility (e.g. opioids, barium, atropine) • Idiopathic megacolon • Ileus due to inflammatory disease • Spinal neoplasia • Electrolyte imbalance (hypercalcemia, hypokalemia, hypomagnesemia)
Metabolic disease	<ul style="list-style-type: none"> • Obesity • Hypothyroidism



The body is 65% to 75% water, depending on a cat's age and percent body fat.

toilet), and possibly metabolic disease (*Table 1*).

EVALUATING THE PATIENT

History

Given the myriad possible causes as well as concurrent problems, getting an appropriate history is very important. Clients may misinterpret straining as tenesmus. Not only is asking about the cat's current diet (type, frequency, appetite) important, but also be sure to ask questions to determine whether the patient might be dehydrated (due to decreased intake or increased water loss), may have orthopedic pain, or may be disinclined to use the litter box because of social or toileting factors (fear, unpleasant box). Download a client form with specific questions to ask to address these possible concerns at length at dvm360.com/ConstipationForm.

Mild constipation does not require a great deal of work-up or treatment, but identifying its causes is relevant for management to reduce the chance for progression. Chronic, recurrent constipation results in dilation of the colon and obstipation, which in some cats becomes irreversible, idiopathic megacolon that is refractory to cure due to loss of normal neuromuscular function (see the sidebar "Chronic course of constipation," page 78).¹



Killing fleas and ticks can be just **this easy.**

With NexGard® (afoxolaner), flea and tick control is convenient for pet owners since dogs love taking the soft, beef-flavored chew.¹

POWERFUL flea and tick killing all month long

CONVENIENT monthly dosing owners are used to

EASY for owners to give¹ and for veterinarians to dispense



Prescription only with anti-diversion technology

See brief summary on page 78

¹Data on File at Merial.



©NexGard is a registered trademark, and
™FRONTLINE VET LABS is a trademark, of
Merial. ©2015 Merial, Inc., Duluth, GA.
All rights reserved. NEX15TRADEADA (01/15).

IMPORTANT SAFETY INFORMATION: For use in dogs only. The most common adverse reaction is vomiting. Other adverse reactions reported are dry/flaky skin, diarrhea, lethargy, and anorexia. The safe use of NexGard in pregnant, breeding, or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures.

NexGard® (afoxolaner) Chewables

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Description:

NEXGARD® (afoxolaner) is available in four sizes of beef-flavored, soft chewables for oral administration to dogs and puppies according to their weight. Each chewable is formulated to provide a minimum afoxolaner dosage of 1.14 mg/lb (2.5 mg/kg). Afoxolaner has the chemical composition 1-Naphthalenecarboxamide, 4-[5-[3-chloro-5-(trifluoromethyl)-phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl].

Indications:

NEXGARD kills adult fleas and is indicated for the treatment and prevention of flea infestations (*Ctenocephalides felis*) and the treatment and control of Black-legged tick (*Ixodes scapularis*), American Dog tick (*Dermacentor variabilis*), and Lone Star tick (*Amblyomma americanum*) infestations in dogs and puppies 8 weeks of age and older, weighing 4 pounds of body weight or greater, for one month.

Dosage and Administration:

NEXGARD is given orally once a month, at the minimum dosage of 1.14 mg/lb (2.5 mg/kg).

Dosing Schedule:

Body Weight	Afoxolaner Per Chewable (mg)	Chewables Administered
4.0 to 10.0 lbs.	11.3	One
10.1 to 24.0 lbs.	28.3	One
24.1 to 60.0 lbs.	68	One
60.1 to 121.0 lbs.	136	One
Over 121.0 lbs.	Administer the appropriate combination of chewables	

NEXGARD can be administered with or without food. Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes to ensure that part of the dose is not lost or refused. If it is suspected that any of the dose has been lost or if vomiting occurs within two hours of administration, redose with another full dose. If a dose is missed, administer NEXGARD and resume a monthly dosing schedule.

Flea Treatment and Prevention:

Treatment with NEXGARD may begin at any time of the year. In areas where fleas are common year-round, monthly treatment with NEXGARD should continue the entire year without interruption.

To minimize the likelihood of flea reinfestation, it is important to treat all animals within a household with an approved flea control product.

Tick Treatment and Control:

Treatment with NEXGARD may begin at any time of the year (see **Effectiveness**).

Contraindications:

There are no known contraindications for the use of NEXGARD.

Warnings:

Not for use in humans. Keep this and all drugs out of the reach of children. In case of accidental ingestion, contact a physician immediately.

Precautions:

The safe use of NEXGARD in breeding, pregnant or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures (see **Adverse Reactions**).

Adverse Reactions:

In a well-controlled US field study, which included a total of 333 households and 615 treated dogs (415 administered afoxolaner, 200 administered active control), no serious adverse reactions were observed with NEXGARD. Over the 90-day study period, all observations of potential adverse reactions were recorded. The most frequent reactions reported at an incidence of > 1% within any of the three months of observations are presented in the following table. The most frequently reported adverse reaction was vomiting. The occurrence of vomiting was generally self-limiting and of short duration and tended to decrease with subsequent doses in both groups. Five treated dogs experienced anorexia during the study, and two of those dogs experienced anorexia with the first dose but not subsequent doses.

Table 1: Dogs With Adverse Reactions.

	Treatment Group			
	Afoxolaner		Oral active control	
	N ¹	% (n=415)	N ²	% (n=200)
Vomiting (with and without blood)	17	4.1	25	12.5
Dry/Flaky Skin	13	3.1	2	1.0
Diarrhea (with and without blood)	13	3.1	7	3.5
Lethargy	7	1.7	4	2.0
Anorexia	5	1.2	9	4.5

¹Number of dogs in the afoxolaner treatment group with the identified abnormality.

²Number of dogs in the control group with the identified abnormality.

In the US field study, one dog with a history of seizures experienced a seizure on the same day after receiving the first dose and on the same day after receiving the second dose of NEXGARD. This dog experienced a third seizure one week after receiving the third dose. The dog remained enrolled and completed the study. Another dog with a history of seizures had a seizure 18 days after the first dose of NEXGARD. The dog remained enrolled and completed the study. A third dog with a history of seizures received NEXGARD and experienced no seizures throughout the study.

To report suspected adverse events, for technical assistance or to obtain a copy of the MSDS, contact Meril at 1-888-637-4251 or www.merial.com/nexgard. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>.

Mode of Action:

Afoxolaner is a member of the isoxazoline family, shown to bind at a binding site to inhibit insect and acarine ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes. Prolonged afoxolaner-induced hyperexcitability results in uncontrolled activity of the central nervous system and death of insects and acarines. The selective toxicity of afoxolaner between insects and acarines and mammals may be inferred by the differential sensitivity of the insects and acarines' GABA receptors versus mammalian GABA receptors.

Effectiveness:

In a well-controlled laboratory study, NEXGARD began to kill fleas four hours after initial administration and demonstrated >99% effectiveness at eight hours. In a separate well-controlled laboratory study, NEXGARD demonstrated 100% effectiveness against fleas on the Day 30, 60 and 90 visits compared with baseline was 98.0%, 99.7%, and 99.9%, respectively. Collectively, the data from the three studies (two laboratory and one field) demonstrate that NEXGARD kills fleas before they can lay eggs, thus preventing subsequent flea infestations after the start of treatment of existing flea infestations.

In well-controlled laboratory studies, NEXGARD demonstrated >94% effectiveness against *Dermacentor variabilis* and *Ixodes scapularis*, 48 hours post-infestation, and against *Amblyomma americanum* 72 hours post-infestation, for 30 days.

Animal Safety:

In a margin of safety study, NEXGARD was administered orally to 8- to 9-week-old Beagle puppies at 1, 3, and 5 times the maximum exposure dose (6.3 mg/kg) for three treatments every 28 days, followed by three treatments every 14 days, for a total of six treatments. Dogs in the control group were sham-dosed. There were no clinically-relevant effects related to treatment on physical examination, body weight, food consumption, clinical pathology (hematology, clinical chemistry, or coagulation tests), gross pathology, histopathology or organ weights. Vomiting occurred throughout the study, with a similar incidence in the treated and control groups, including one dog in the 5x group that vomited four hours after treatment.

In a well-controlled field study, NEXGARD was used concomitantly with other medications, such as vaccines, anthelmintics, antibiotics (including topicals), steroids, NSAIDs, anesthetics, and antihistamines. No adverse reactions were observed from the concomitant use of NEXGARD with other medications.

Storage Information:

Store at or below 30°C (86°F) with excursions permitted up to 40°C (104°F).

How Supplied:

NEXGARD is available in four sizes of beef-flavored soft chewables: 11.3, 28.3, 68 or 136 mg afoxolaner. Each chewable size is available in color-coded packages of 1, 3 or 6 beef-flavored chewables.

NADA 141-406, Approved by FDA

Marketed by: Frontline Vet Labs™, a Division of Merial Limited.

Duluth, GA 30096-4640 USA

Made in Brazil.

1050-4493-02

Rev. 4/2014

©NexGard is a registered trademark, and TMFRONTLINE VET LABS is a trademark, of Merial. ©2014 Merial. All rights reserved.

FRONTLINE VET LABS

FELINE CONSTIPATION peer-reviewed



Physical examination

On examination, hydration is assessed by assessing skin elasticity plus coat luster, mucous membrane moisture, and eye position (*Table 2*). Skin elasticity can be misleading in older patients (as well as young kittens) because of age-related changes in body water distribution, elastin, and collagen. Body weight, weight change relative to previous evaluation,

body condition score (indicating percentage body fat), and muscle condition score (indicating protein adequacy) help determine progression of dehydration as well as amounts needed to rehydrate the individual.

Diagnostic testing

If a cat is experiencing its first episode of uncomplicated constipation, further testing may not be needed and therapeutic rehydration will likely be adequate. For recurrent constipation or when complications such as trauma or degenerative joint disease (DJD) or neurologic signs are present, additional steps are recommended. A minimum database consisting of a complete blood count (CBC), serum chemistry profile, total thyroxine (T₄) concentration measurement, and urinalysis should be performed to assess overall metabolic status and to get more information regarding the degree of dehydration.

Abdominal palpation reveals the presence of firm feces in the colon unless the feces is hidden in the pelvic rectum. Radiographs are required to confirm that the firm mass is intraluminal as well as to identify possible extraluminal problems such as obstructive masses or

orthopedic or skeletal problems. Spondylosis deformans of the lumbosacral vertebral column as well as pain from degenerative changes in the shoulders, elbows, hips, stifles, or hocks may limit mobility, making it harder to get to the litter box or to squat comfortably. Evidence of pelvic fracture or other poorly aligned fractures may be observed.

Table 2

Estimate of dehydration*

Degree of deficit relative to euhydrated state	Physical examination findings
Mild: About 5%	Slightly tacky mucous membranes or saliva, minimal loss of skin turgor, normal eye position
Moderate: About 8%	Dry mucous membranes, moderate loss of skin turgor, mildly sunken eyes
Severe: 10% or more	Extremely dry mucous membranes, skin not returning to original position when tented, severely sunken eyes, weak and thready pulses, tachycardia, hypotension, altered level of consciousness

*Source: Davis H, Jensen T, Johnson A, et al. 2013 AAHA/AAFP Fluid therapy guidelines for dogs and cats. *J Am Anim Hosp Assoc* 2013;49:149-159.

The steps in treating constipation in cats

Rehydrate the cat and maintain hydration.

Remove the feces by enema or manual extraction.

Modify the cat's diet (canned low residue diet, psyllium-enhanced dry diet).

Institute laxative therapy.

Administer promotility drugs.

Sedation may be helpful, allowing gentle manipulation of joints to assess whether range of motion is restricted or if pain is present. All cats with recurrent constipation should have a digital rectal examination. This helps to assess abnormalities of the anal glands, prostate, and pelvic inlet and the presence of rectal diverticulum, polyps, or other obstructive masses. Chronic tenesmus can result in perineal herniation.

Abdominal ultrasonography is useful to assess motility, to further examine abdominal structures, and to collect fine-needle biopsy samples of suspicious lesions. Colonoscopy may be required to biopsy mural or intraluminal masses. Computed tomography or magnetic resonance imaging may be used if an intrapelvic lesion is present or if neurologic deficits are present.

Cats with evidence of

neurologic problems (e.g. paraparesis, hyporeflexia, urinary retention, regurgitation) should have a complete neurologic examination to rule out sacrocaudal dysgenesis (e.g. Manx breed), spinal neoplasia, or dysautonomia.

TREATING A CONSTIPATED CAT

There are five steps involved in relieving constipation in cats (see the sidebar "The steps in treating constipation in cats" for an overview of the treatment process).

Step 1: Rehydration

The cornerstone of therapy for constipation is rehydration and maintenance of a hydrated state. Fluid therapy for rehydration may consist of intravenous fluids, but subcutaneous therapy is generally adequate. The volume of fluid needed to correct the fluid deficit is

Case example: Fluid volume for deficit correction and hydration maintenance*

Patient: A 12-lb (5.4-kg) dehydrated cat with an approximately 5% deficit whose normal, hydrated weight is 13.3 lb (6 kg).

Deficit = $0.05 \times 6 \text{ kg hydrated weight} = 0.3 \text{ L} = 300 \text{ ml}$
 + Maintenance = $60 \text{ ml/kg/day} \times 6 \text{ kg} = 360 \text{ ml}$
 Total: 660 ml in first 24 hours

After rehydration, for maintenance: This rehydrated 13.3-lb (6-kg) cat needs 360 ml/day. If the cat eats canned food (5.5 oz/156 g with 80% water = 124 ml water), only an additional 236 ml of fluids are needed.

*Source: Davis H, Jensen T, Johnson A, et al. 2013 AAHA/AAFP Fluid therapy guidelines for dogs and cats. *J Am Anim Hosp Assoc* 2013;49:149-159.

based on the patient's previous hydrated weight. If not known, the total protein concentration in conjunction with packed cell volume may be helpful.

An isotonic polyionic fluid (e.g. lactated Ringer's solution) is appropriate for rehydration subcutaneously. A replacement solution such as Normosol-R (Hospira) or Plasma-Lyte 148 (Baxter) would be better choices should the intravenous route be used. A maintenance solution is preferable for ongoing maintenance therapy to prevent hyponatremia and hypokalemia, but if subcutaneous use results in discomfort, lactated Ringer's solution may be considered. The volume required for maintaining hydration is 60 ml/kg normal, hydrated weight/day (see the sidebar "Case example: Fluid

volume for deficit correction and hydration maintenance").²

Step 2: Feces removal

Removal of the feces with enemas or manual extraction may be done while the patient is being rehydrated. But do not start dietary therapy, prokinetic agents, and laxatives until the patient has been rehydrated. This is because dietary fiber and medical therapy increase fecal water or interfere with the colon's attempts to resorb water needed for cellular hydration.³

Administering smaller volumes (e.g. 35 ml) of warm water (or saline solution) mixed with 5 ml of mineral oil, glycerin, polyethylene glycol (PEG or PEG 3350), lactulose, or docusate sodium several times throughout a 24-hour period

is safer and more effective than administering the entire volume as a bolus.¹ Because docusate sodium increases absorption of intraluminal contents into the bloodstream, it should not be administered concurrently with mineral oil.

Pediatric rectal suppositories can also be used (e.g. bisacodyl, docusate sodium). If the patient is anesthetized or sedated for rectal manipulation (digital examination, manual fecal extraction, or enema administration), use a cuffed endotracheal tube to prevent aspiration from vomiting.

Step 3: Dietary therapy

Soluble fibers (e.g. pectin, oligosaccharides) are capable of adsorbing (binding) water and forming a gel. Insoluble fibers increase fecal bulk, resulting in distention and reflex contraction. Both interfere with water reabsorption into the body and should only be considered when a patient is well-hydrated. Different fiber sources have different soluble:insoluble proportions.

Fibers can also be characterized by differences in fermentability. This refers to the ability of intestinal bacteria to produce short-chain fatty acids (SCFA) and gas from the fiber. Moderately fermentable fibers such as beet pulp are preferable to a highly ferment-

able, high-gas-forming fiber source.⁴⁻⁶ SCFAs are vital as an energy source for colonocytes and are key in motility.

While a psyllium-enhanced dry diet has been shown to be effective in treating constipation,⁷ increasing water intake by including wet foods and increasing desirable water stations in the home is beneficial. As with all things in cats, individualization is critical. Regardless of which diet is chosen, reassess the patient to ensure that the diet is having the desired effect.

Step 4: Laxative administration

Cathartics are agents that increase colonic motility. They include hyperosmotic laxatives such as polysaccharides (e.g. lactulose) and PEGs or those that irritate and stimulate the mucosa (e.g. vegetable oils, sennoside, glycerin).

True laxatives act by other mechanisms. Lubricating laxatives (e.g. mineral oil, hairball remedies) impair water absorption from the colon into the body; emollient laxatives (e.g. anionic detergent such as docu-

sate sodium) enhance absorption of lipid into the body, but impede water absorption into the body; bulk-forming laxatives (e.g. cellulose or poorly digestible polysaccharides such as cereal grain) increase fecal bulk, fermentation, and viscosity.

Step 5: Promotility drug administration

Consider promotility drugs after other therapies have been instituted and shown to be insufficient. Cholinergic agents (e.g. bethanechol) have undesirable side effects and cannot be

Finally!

A Simple, Once-a-Week Product to Manage Otitis External!

Treating painful, irritated ears each day is no picnic for a dog or owner. New CAMEO™ Otic's weekly application is the solution.

CAMEO's antimicrobial activity is optimized in an all-natural, proprietary blend of Organum, Cassia, Clove Bud and Eucalyptus to:

- Kill more than 99% of susceptible strains of yeast and bacteria*, including *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Malassezia pachydermatis*
- Maximize coverage of the ear canal by becoming fluid at body temperature
- Manage recurring otitis externa, as needed

Ask your distributor representative about the once-a-week solution you've been waiting for: CAMEO™ Otic.

	Manages <i>Pseudomonas aeruginosa</i>	No Antibiotics or Steroids	Once-A-Week Dosing (Lasting effect for up to 7 days)
CAMEO™ Otic	✓	✓	✓
Animax®			
Baytril® Otic	✓		
EasOtic®			
Mometamax/Otomax®	✓		
Surolan®			
Tresaderm®	✓		



800.874.9764
prnpharmaceutical.com/comeo

*Data on file. CAMEO™ is a trademark and PRN® is a registered trademark of Pegasus Laboratories, Inc. 11/14 03691

Key point: Stretching or irritation of the colon may result in vomiting. A cuffed endotracheal tube should be in place when administering enemas, manipulating feces, or examining a cat's rectum under anesthesia.

recommended.⁸ Drugs affecting serotonin 5-HT₄ receptors (*e.g.* cisapride, mosapride, prucalopride, tegaserod) have been used to effect.⁹⁻¹¹ These should be given orally, as the transdermal route fails to deliver therapeutic levels.¹¹ Experimentally, nizatidine and ranitidine inhibit anticholinesterase activity, acting synergistically with cisapride.¹²

If the patient has concurrent medical problems, it may be receiving other medications that might exacerbate constipation. These include those that increase dehydration, such as diuretics, and those that interfere with intestinal motility, such as anticholinesterase and sympathomimetic agents, barium, opioids, tricyclic antidepressants, and some H₁-antihistamines.

WHAT ROLE DOES THE ENVIRONMENT PLAY?

A basic environmental need is to have multiple but separated resources.¹³ These include duplicates each of water, food, litter boxes or outside latrines, perches, resting areas, and toy stations. By having multiple sites, separate from each other,

the chance of intercat aggression or threat (perceived or real) from other individuals is minimized. Having unhooded litter boxes is important to eliminate the risk of ambush.

Litter boxes need to be large (at least 1.5 times the length of the cat) and very clean. The litter boxes—and all resource stations—need to be easy to access, especially for a cat that is mobility-restricted (*e.g.* due to DJD).

Water stations must also be kept clean and freshened regularly. Feeding small amounts of food frequently results in cats drinking a greater volume of water.¹⁴ Wet food increases water intake significantly, favoring a positive hydration status.

TO CUT IS TO CURE?

Colectomy should be considered a “last resort” for a cat with megacolon that is refractory to medical management and has been struggling with obstipation for more than six months. If pelvic trauma resulting in malunion occurred more than six months earlier, colectomy is likewise justified.

Should pelvic trauma have occurred less than six months

ago, however, pelvic osteotomy may be all that is required to prevent megacolon from developing in cats.

Colectomy is a procedure with significant potential complications and should be referred to a surgeon with advanced soft tissue and anastomosis skills whenever it's possible.

SUMMARY

Early correction and management of constipation will help prevent irreversible problems from developing. The effects of all drugs and dietary manipulations depend on the patient being adequately hydrated. Behavioral and environmental aspects should not be overlooked.

Clean, attractive litter boxes that are safe and easy to access not only enhance a positive quality of life but also prevent retention of feces or inappropriate elimination.

Regular follow-up is very important. Assessing the effect of the recommendations on the individual and making adjustments as warranted will provide the best outcome. **VM**

*Margie Scherk, DVM, DABVP
(feline practice)
catsINK
Vancouver, Canada*

View the references for this article at **dvm360.com/CatConstipation**.



Clinic form

Don't forget to download a client form for collecting a history in cats with constipation at **dvm360.com/ConstipationForm**.




innovative whole team, whole practice continuing education sessions

ANNOUNCING

five don't-miss innovative session tracks from CVC.

dvm360 Full Circle seminars: Critical Topics, Multiple Perspectives
Learn then Earn: Connect Clinical + Practice Management Concepts
Your Practice Presence: Get Online & Go Off the Chart
In This Case: Real Discussions, Real Results
Expert²: The Power of Interaction

Each session is developed to support the way you practice veterinary medicine today.
All are CVC  Two-way Learning Sessions, built using education techniques that:

- Personalize session content to meet your greatest needs right now
- Invite maximum interaction between speakers and attendees
- Deliver optimum take-home value!

Visit www.TheCVC.com and look for the  Two-way Learning icon!

Register to attend CVC Washington, D.C. by March 11, 2015 and save up to \$100 on a four-day registration.



WASHINGTON
DC
A P R I L
23-26, 2015

KANSAS
CITY
AUGUST
28-31, 2015

**SAN
DIEGO**
DECEMBER
3-6, 2015

CALL 800.255.6864, ext. 6 **CLICK** TheCVC.com **EMAIL** cvc@advanstar.com **FOLLOW**





DENTAL PRODUCTS

LEBALAB

Search

LEBA III™

Have you Discovered Leba III?

100% Response in Double Blind Tests
See the Results on www.lebalab.com


35 Days Later



Before

After

28 Days Later



Before

After



Cleans Teeth with the Ease of a Spray

The LebaLab difference:

Leba III stimulates the good flora in the saliva. The longer Leba III is used, the cleaner the teeth and the healthier the chemistry of the mouth becomes. Antibacterial products kill the good bacteria in the mouth leading to imbalance and repeated dental procedures.

Pets ingest dental products, they cannot rinse. They can become subject to the side effects of the components, that's why Leba III contains no Grapefruit Seed Extract, no chlorides or chemical agents.

Used by veterinarians since 1994.

To order, call toll free: 1-866-532-2522

www.lebalab.com | tellus@lebalab.com | Questions? Call 1-519-542-4236

LebaLab Inc.



Veterinary medicine

Essential medicine for exemplary patient care

Content Licensing for Every Marketing Strategy



Marketing solutions fit for:

- Outdoor
- Direct Mail
- Print Advertising
- Tradeshow/POP Displays
- Social Media
- Radio & Television

Logo Licensing | Reprints | Eprints | Plaques

Leverage branded content from *Veterinary Medicine* to create a more powerful and sophisticated statement about your product, service, or company in your next marketing campaign. Contact Wright's Media to find out more about how we can customize your acknowledgements and recognitions to enhance your marketing strategies.

For more information, call Wright's Media at
877.652.5295 or visit our website at
www.wrightsmmedia.com

ANESTHESIA EQUIPMENT

BLUEPRINT FOR BREATHING

Anesthesia made simple... A.D.S. 2000



Proudly made in
the U.S.A.



Revolutionary Veterinary Breakthrough

- Anesthesia Machine (Positive Pressure)
- Electronically microprocessor controlled
- Delivery & Ventilation for small animal use
- Automatically sets breathing parameters
- Very affordable and easy to use
- Just connect to vaporizer & Oxygen
- Two year parts & labor warranty
- Free lifetime loaner service

**NEWLY ADDED
FEATURE !!!**

12 Hour Battery
backup providing
portability and protection



In Business
Since 1964

1099 East 47th Street - Hialeah, Florida 33013 USA

800-445-8581 - FAX 305-685-7671

www.englerusa.com

MEDICAL EQUIPMENT

CALL US FOR A
FREE SAMPLE



BiteNot
The collar that cares

**The Comfortable Alternative
to the Elizabethan Cone**

— Available from Distributors —
Call us for a free sample.

1-800-424-8366

www.bitenot.com

dvm360.com



For a *quick* tie down, use a **leash**

For a quick tie down for a cat undergoing abdominal surgery, place a leash across the table at the point where the cat's neck will be, with the ends of the leash secured to the table. Place the cat on the table with its neck and legs on top of the leash, and then tuck the legs under the leash. The cat's weight is sufficient to hold the legs and keep the patient in dorsal recumbency. The whole process takes about five seconds!

*Dr. Gary Camp
Tampa, Florida*



We need your ideas!
We'll pay \$50 for regular submissions and \$75 for videos that we publish in print or online.

Email vm@advanstar.com, fax us at (913) 273-9876, or write to Idea Exchange Editor at 8033 Flint, Lenexa, KS 66214.

Numb ear = happier cat = better glucose curve

Diabetic cats understandably start getting difficult after being subjected to repeated ear pricks for in-clinic glucose curves. We have found that numbing the ear we will be pricking by applying a topical anesthetic cream or spray improves the cat's comfort and attitude considerably. And, in our experience, the glucose curves of a happy cat are more reliable than are those of an upset cat.

*Dr. Anita Poling
Avon, Ohio*



Read the latest Miller online




Will the real Dr. Miller please stand up?

Dr. Miller muses on the commonality of his name in this blast from the past at dvm360.com/miller.

Also online...

An all-new interactive case featuring Ivy, the nighttime food thief, at dvm360.com/case14.



1.8 mg/mL

For subcutaneous use in cats

BRIEF SUMMARY: Before using SIMBADOL, please consult the full prescribing information, a summary of which follows.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

HUMAN SAFETY WARNING

Abuse Potential

SIMBADOL contains buprenorphine (1.8 mg/mL), an opioid agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. Buprenorphine has certain opioid properties that in humans may lead to dependence of the morphine type. Abuse of buprenorphine may lead to physical dependence or psychological dependence. The risk of abuse by humans should be considered when storing, administering and disposing of SIMBADOL. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (suicidal depression).

Life-Threatening Respiratory Depression

Respiratory depression, including fatal cases, may occur with abuse of SIMBADOL.

Additive CNS Depressant Effects

SIMBADOL has additive CNS depressant effects when used with alcohol, other opioids, or illicit drugs that cause central nervous system depression.

Accidental Exposure

Because of the potential for adverse reactions associated with accidental injection, SIMBADOL should only be administered by veterinarians or veterinary technicians who are trained in the handling of potent opioids.

See Human Safety for detailed information.

INDICATION: SIMBADOL is indicated for the control of postoperative pain associated with surgical procedures in cats.

DOSAGE AND ADMINISTRATION: The dosage of SIMBADOL is 0.24 mg/kg (0.11 mg/lb) administered subcutaneously once daily, for up to 3 days. Administer the first dose approximately 1 hour prior to surgery. Do not dispense SIMBADOL for administration at home by the pet owner (see Human Safety).

CONTRAINDICATIONS: SIMBADOL is contraindicated in cats with known hypersensitivity to buprenorphine hydrochloride or any of the components of SIMBADOL, or known intolerance to opioids.

WARNINGS: For subcutaneous (SQ) injectable use in cats.

Human Safety: Not for use in humans. Keep out of reach of children.

Because of the potential for adverse reactions, hospital staff should avoid accidental exposure and contact with skin, eyes, oral or other mucous membrane during administration. SIMBADOL contains buprenorphine, a mu opioid partial agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. SIMBADOL can be abused and is subject to misuse, abuse, addiction and criminal diversion. SIMBADOL should be handled appropriately to minimize the risk of diversion, including restriction of access, the use of accounting procedures, and proper disposal methods, as appropriate to the clinical setting and as required by law. Abuse of SIMBADOL poses a hazard of overdose and death. This risk is increased with concurrent abuse of alcohol and other substances including other opioids and benzodiazepines. Buprenorphine has been diverted for non-medical use into illicit channels of distribution. All people handling opioids require careful monitoring for signs of abuse. Drug abuse is the intentional non-therapeutic use of a prescription drug for its rewarding psychological or physiological effects. Abuse of opioids can occur in the absence of true addiction. Naloxone may not be effective in reversing respiratory depression produced by buprenorphine. The onset of naloxone effect may be delayed by 30 minutes or more. Doxapram hydrochloride has also been used as a respiratory stimulant.

PRECAUTIONS: Hyperactivity (opioid excitation) has been observed up to 8 hours after anesthetic recovery (see ADVERSE REACTIONS). Safety has not been evaluated in moribund cats. Use in such cases should be based on the risk-benefit assessment of the veterinarian. Use with caution in cats with impaired hepatic function. The use of SIMBADOL has not been evaluated in breeding, pregnant, or lactating cats, or in cats younger than 4 months of age.

ADVERSE REACTIONS: In two controlled field studies, the following adverse reactions were reported.

Adverse Reactions in Two Field Studies

Adverse Reaction ^a	SIMBADOL (N = 224)		Control (N = 226)	
	During Surgery ^b	After Surgery	During Surgery ^b	After Surgery
Hypotension ^c	68 (30.4%)	51 (22.8%)	60 (26.5%)	40 (17.7%)
Tachycardia ^d	55 (24.6%)	73 (32.6%)	30 (13.3%)	44 (19.5%)
Hypothermia ($\leq 98.0^{\circ}\text{F}$)	38 (17.0%)	1 (0.4%)	47 (20.8%)	0
Hyperthermia ($\geq 103.0^{\circ}\text{F}$)	1 (0.4%)	91 (40.6%)	0	33 (14.6%)
Hypertension ^e	10 (4.5%)	40 (17.9%)	17 (7.5%)	18 (8.0%)
Anorexia	0	40 (17.9%)	0	35 (15.5%)
Hyperactivity	0	26 (11.6%)	0	11 (4.9%)
Reduced SpO ₂ ($\leq 90\%$)	8 (3.6%)	1 (0.4%)	11 (4.9%)	0
Bradycardia (≤ 90 beats/min)	5 (2.2%)	1 (0.4%)	4 (1.8%)	1 (0.4%)
Tachypnea (≥ 72 breaths/min)	0	5 (2.2%)	1 (0.4%)	6 (2.7%)
Arrhythmia	1 (0.4%)	1 (0.4%)	2 (0.9%)	0
Blindness	0	2 (0.9%)	0	1 (0.4%)
Apnea/Death	1 (0.4%)	1 (0.4%)	0	0
Ataxia	0	1 (0.4%)	0	0
Hyperesthesia	0	1 (0.4%)	0	0

a. Cats may have experienced more than one type or occurrence of an adverse reaction. Cats experiencing the same reaction both during and after surgery are presented in both time periods.

b. During surgery is the time from the administration of the anesthetic induction agent until discontinuation of the gas anesthetic.

c. Hypotension is defined as a mean blood pressure of ≤ 60 mmHg during surgery and ≤ 90 mmHg after surgery.

d. Tachycardia is defined as a heart rate of ≥ 180 beats per minute during surgery and ≥ 200 beats per minute after surgery.

e. Hypertension is defined as a mean blood pressure of ≥ 120 mmHg during surgery and ≥ 160 mmHg after surgery.

To report suspected adverse events, contact Abbott Animal Health at 1-888-299-7416, FDA at 1-888-FDA-VETS or FDA online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>.

EFFECTIVENESS: The effectiveness of SIMBADOL was demonstrated in two randomized, masked, placebo-controlled, multi-site field studies involving client-owned cats of various breeds. A descriptive, interactive pain assessment system was used by the trained assessor over the 72-hour post-operative period to determine pain control, and treatment success was defined as a cat that completed the 72-hour post-operative period without rescue analgesia. A statistically significant difference ($P \leq 0.005$) in the number of successes in the treatment group over the placebo control group was observed. The results of two field studies demonstrate that SIMBADOL is effective and has an acceptable safety margin for the control of postoperative pain in cats.

HOW SUPPLIED: SIMBADOL (buprenorphine injection) is supplied in a carton containing one 10 mL amber glass vial. Each multidose vial contains 1.8 mg/mL of buprenorphine.

NADA 141-434, Approved by FDA

SIMBADOL is a trademark of Abbott Laboratories.

Manufactured for: Abbott Laboratories, North Chicago, IL 60064 USA
Product of United Kingdom

© 2014 Abbott Laboratories.

All Rights Reserved.

Presenting FDA Approved



Simbadol™

(buprenorphine injection)



Once-daily



24-hour



surgical pain control



- The first and only buprenorphine **FDA approved for cats**
- Demonstrated safety and efficacy in **more than 200 cats** treated with SIMBADOL
- Up to 3 once-daily subcutaneous doses for a **total of 72 hours of pain control**

INDICATION: SIMBADOL is indicated for the control of postoperative pain associated with surgical procedures in cats.

IMPORTANT SIMBADOL (buprenorphine injection) SAFETY INFORMATION

WARNINGS, PRECAUTIONS and CONTRAINDICATIONS: Due to serious human safety and abuse concerns, including physical or psychological dependence, life-threatening respiratory depression and additive CNS depressant effects, read the full prescribing information before using this drug, including the complete Boxed Warning. Not for use in humans. Hospital staff should be trained in the handling of potent opioids and should avoid accidental exposure. For subcutaneous (SQ) injectable use in cats. Opioid excitation has been observed up to 8 hours after anesthetic recovery. Use with caution in cats with impaired hepatic function. SIMBADOL has not been evaluated in breeding, pregnant, or lactating cats, in cats younger than 4 months of age or moribund cats. Do not use in cats with known hypersensitivity to buprenorphine hydrochloride or any of the components of SIMBADOL, or known intolerance to opioids.

ADVERSE REACTIONS: In two controlled field studies, the most frequent adverse reactions with SIMBADOL were hypotension, tachycardia, hypothermia, hyperthermia, hypertension, anorexia, and hyperactivity. Less frequent but serious adverse reactions included two deaths following apnea and two reports of presumptive post-anesthetic cortical blindness. See the full prescribing information for a complete list and additional details of adverse reactions for each field study.

See the Brief Summary of full prescribing information, including the complete Boxed Warning for human safety, on following page.

